Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Frailty score based on age, Charlson Comorbidity Index, ECOS PS predicts outcomes in FIRST trial.
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
Cardiopulmonary adverse events with carfilozmib treatment included dyspnea, hypertension, peripheral edema, cough, pneumonia, and heart failure.
Patients who received isatuximab experienced a median progression-free survival of 11.5 months compared with 6.5 months in patients who did not receive isatuximab.
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
This dose-finding study examined a bispecific antibody targeting BCMA and CD3 in patients with R/R multiple myeloma.
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Only about one-third of patients required hospital admission.
Researchers developed and tested a risk stratification model based on hematopoietic variables that can be obtained from a complete blood count.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Progression-free survival significantly longer with lenalidomide compared with observation
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Increased hospital activity unrelated to hematology seen for years before diagnosis
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Prolonged closure time and defects in von Willebrand factor were identified as risk factors for bleeding complications patients with multiple myeloma.
Researchers conducted a subgroup analysis of Asian patients with relapsed or refractory multiple myeloma who received carfilzomib in 2 phase 3 clinical trials.
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.
A case series study demonstrated the importance of timely, preventive dental assessment for patients with multiple myeloma.
Patients who were treated with carfilzomib, dexamethasone, and daratumumab had not reached median progression-free survival at the cutoff date.
An analysis of completion rates for PRO measures among patients with multiple myeloma found that reminders and use of preferred delivery mode influence response rate.
Advances in technology for detecting measurable residual disease (MRD) are also raising questions regarding the role of MRD in managing multiple myeloma.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
A retrospective cohort study identified real-world epidemiology, treatment patterns, and survival outcomes in patients with multiple myeloma in Israel.
Irreversible proteasome inhibitor carfilzomib appears to cause reticulocytosis in multiple myeloma by inhibiting terminal erythroid maturation.
Patients who received autologous transplant followed by allogeneic transplant experienced improved progression-free survival.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Plitidepsin plus dexamethasone yielded improved progression-free and overall survival compared with dexamethasone alone.
Factors associated with poor adherence to specific guideline-recommended supportive care measures involved patient race and site of care.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
All-oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
Cardiovascular adverse events were more common with carfilzomib therapy and within the first 3 months of treatment.
For patients receiving drug therapy, economic burden substantial across lines of therapy
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Progressive MGUS and light-chain MGUS were both associated with skewed serum free light chain ratios.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Very good partial response or better was seen in nearly two-thirds of patients receiving the triplet treatment.
Patients who were naive to daratumumab experienced an overall response rate of 91.7%; median progression-free survival in this cohort was not reached.
Continued approval of Xpovio for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Median overall survival was 3.6 years for patients who received upfront therapy and 4.2 years for patients who did not.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.